Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors
US11230526B1 · kind B1 · utility
1Cited by
2References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2019 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Mar 5, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D333/16
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.